Выводы. 
Полиморфизм промоторной области гена APT(однонуклеотидный полиморфизм Fas-670A/G)

• — Выявлены аллельные варианты промоторной области гена APT-1 (однонуклеотидный полиморфизм Fas-670A/G) в клетках опухолевого очага больных раком толстого кишечника методом прямого определения нуклеотидной последовательности.
• — При разработке метода аллельспецифической ПЦР для анализа однонуклеотидного полиморфизма -670A/G промоторного участка гена Fas подобран оптимальный температурный режим (62єС), количество циклов ПЦР (45) и специфические праймеры.

Список литературы

• 1. Новиков В. В., Добротина Н. А., Бабаев А. А. Иммунология. Н. Новгород: ННГУ им. Н. И. Лобачевского, 2005. 239 с.
• 2. Ребриков Д. В., Саматов Г. А., Трофимов Д. Ю. и др. ПЦР «в реальном времени» М.: БИНОМ, 2009. 223 с.
• 3. Broen J., Gourh P., Rueda B. et al. The FAS -670A>G polymorphism influences susceptibility to systemic sclerosis phenotypes // Arthritis. Rheum. 2009. Vol.60. Р.3815−3820.
• 4. Cao Y., Miao X.P., Huang M.Y. et al. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma // Mol. Carcinog. 2010.Vol.49. P.944−950.
• 5. Cheng J., Liu C., Koopman W.J. et al. Characterization of human Fas gene. exon/intron organization and promoter region // J. Immunol. 1995. Vol.154. Р.1239−1245.
• 6. Colella S., Yau C., Taylor J.M. et al. Making SNPs make sense // Pharmacogenetics. 2011. Vol. 12. P.1−2.
• 7. De Maria R., Boirivant M., Cifone M.G. et al. Functional expression of Fas and Fas ligand on human gut lamina propria T lymphocytes. A potential role for the acidic sphingomyelinase pathway in normal immunoregulation // J. Clin. Invest. 1996. Vol. 97. P.316−322.
• 8. Engelmark M. T., Renkema K. Y., Gyllensten U. B. No Evidence of the Involvement of the Fas-670 Promoter Polymorphism in Cervical Cancer In Situ // Int. J. Cancer. 2004. Vol.112. P.1084−1085.
• 9. Geleijnsab Karin, Lamanb Jon D., Rijsab Wouter van et al. Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain-Barrй syndrome (GBS) // Journal Home. 2005. Vol.161. P.183−189.
• 10. Hampe J., Shaw S.H., Saiz R. et al. Linkage of inflammatory bowel disease to human chromosome 6p. // Am. J. Hum. Genet. 1999. Vol.65. P.1647−1655.
• 11. Hanasaki Hiroko, Takemura Yukihiro, Fukuo Keisuke et al. Fas promoter region gene polymorphism is associated with an increased risk for myocardial infarctionFas gene polymorphism in cardiovascular disease // Hypertension Research. 2009. Vol.32. Р.261−264.
• 12. Hofmann Guenter, Langsenlehner Uwe, Langsenlehner Tanja. A common hereditary single nucleotide polymorphism in the gene of FAS and colorectal cancer survival // Journal of Cellular and Molecular Medicine.2009. Vol.10. P.1−12.
• 13. Huang Q.R., Morris D., Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene // Mol. Immunol. 1997. Vol.34. P.577−582.
• 14. Jrad B. B. H, Wijden M., Noureddine B. et al. A polymorphism in FAS gene promoter associated with increased risk of nasopharyngeal carcinoma and correlated with anti-nuclear autoantibodies induction // Cancer Letters. 2006. Vol.233. P. 21−27.
• 15. Jung Yong Jin, Kim Yoon Jun, Kim Lyoung Hyo et al. Putative Association of Fas and FasL Gene Polymorphisms with Clinical Outcomes of Hepatitis B Virus Infection // Intervirology. 2007. Vol. 50. Р. 369−376.
• 16. Kanemitsu S., Ihara K., Saifddin A. et al. A functional polymorphism in Fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus // J. Rheumatol. 2002. Vol.29. P.1183−1188.
• 17. Kang Sung Wook, Chung Joo-Ho, Kim Dong Hwan et al. A Promoter SNP (rs1800682, -670C/T) of FAS Is Associated with Stroke in a Korean Population // Genomics & Informatics. Vol. 8, № 4. P.206−211.
• 18. Kelly J. A., Pociot F., Moser K. L. et al. Functional promoter haplotypes of the human FAS gene are associated with the phenotype of SLE characterized by thrombocytopenia // Genes and Immunity. 2005. Vol. 6. P.699−706.
• 19. Kim K.M., Lee K., Hong Y.S., Park H.Y. Fas-mediated apoptosis and expression of related genes in human malignant hematopoietic cells // Exp. Mol. Med. 2000. Vol.32. Р.246−254.
• 20. Kruglyak L., Nickerson, D.A. Variation is the spice of life. Nat. Genet. 2001. Vol.27. P. 234−236.
• 21. LaFramboise Th. Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances // Nucleic Acids Research. 2009. Vol. 37, № 13. P. 4181−4193.
• 22. Lee Y.H., Ji J.D., Sohn J., Song G.G. Polymorphsims of CTLA-4 exon 1 +49, CTLA-4 promoter -318 and Fas promoter -670 in spondyloarthropathies // Clin. Rheumatol. 2001. Vol.20. P.420−422.
• 23. Leithauser F., Dhein J., Mechtersheimer G. et al. Constitutive and induced expression of Apo-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells // Lab. Invest. 1993. Vol.69. Р.415−429.
• 24. Lerma E., Romero M., Gallardo A. et al. Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma // Medicine. 2011.Vol. 452, № 1. P.65−74.
• 25. Liakouli V., Manetti M., Pacini A. et al. The ?670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis // Ann. Rheum. Dis. 2009. Vol.68. P.584−590.
• 26. Nagata S. Apoptosis regulated by a death factor and its receptor: Fas ligand and Fas // Philos. Trans. R. Soc. Lond. B. Biol. Sci. 1994. Vol.354. Р.281−287.
• 27. Nagata S. Fas ligand-induced apoptosis // Annu. Rev. Genet. 1999. Vol.33. P.29−55.
• 28. Niino M., Kikuchi S., Fukazawa T. et al. An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis // BMC Neurology. 2002. Vol.2. P.8.
• 29. Perkin Elmer. SNP and Genotyping Overview // Pharmacogenomics. 2005. Vol. 12. Р.1.
• 30. Rudert F., Visser E., Forbes L. et al. Identification of a silencer, enhancer, and basal promoter region in the human CD95 (Fas/Apo-1) gene // DNA Cell. Biol. 1995. Vol.14. Р.931−937.
• 31. Sibley K., Rollinson S., Allan J.M. et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia // Cancer Res. 2003. Vol.63. P.4327−4330.
• 32. Smith Kaleigh. Genetic Polymorphism and SNPs // Functional Genomics and Proteomics. 2002. Vol.14. Р.21.
• 33. Sun T., Zhou Y., Li H. et al. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer // J. of Experimental Medicine. Vol. 202, № 7. P.967−974.
• 34. Ueda M., Terai Y., Hung Y.C. Fas gene promoter -670 polymorphism (A/G) is associated with cervical carcinogenesis // Gynecol. Oncol. 2005. Vol.98, № 1. P.129−133.
• 35. Urquhart J. SNPs on display // Nano Letters. 2011. Vol.10. Р.1021.
• 36. Wang Meilin, Wu Dongmei, Tan Ming et al. FAS and FAS Ligand Polymorphisms in the Promoter Regions and Risk of Gastric Cancer in Southern China // Biochem. Genet. 2009. Vol.47. P.559−568.
• 37. Wasfi Y.S., Silveira L.J., Jonth A. et al. Fas promoter polymorphisms: genetic predisposition to sarcoidosis in African-Americans // Tissue Antigens. 2008. Vol.72, № 1. P.39−48.
• 38. Yang Ming, Sun Tong, Wang Li et al. Functional Variants in Cell Death Pathway Genes and Risk of Pancreatic Cancer // Clin. Cancer Res. 2008. Vol.14, № 10. P.3230−3236.
• 39. Zhang Zhizhong, Xue Hengchuan, Gong Weida et al. FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies // Carcinogenesis. 2009. Vol.30, № 3 P.487−493.
• 40. Zhu Q., Wang T., Ren J. et al. FAS-670A/G polymorphism: A biomarker for the metastasis of nasopharyngeal carcinoma in a Chinese population // Clin. Chim. Acta.2010. Vol.411. P.179−183.

Размещено на Allbest.ru.